Windtree Therapeutics to Sell Cardiovascular Pipeline Assets
Windtree Therapeutics has agreed to sell its cardiovascular biotech pipeline assets to Seismic Pharmaceuticals under a deal that includes a potential USD 700,000 contingent payment, transfer of certain development payables, and Windtree retaining a 20 percent share of any future milestone, royalty, or global commercial revenue generated from the assets.
Cardiovascular Pipeline Assets | 26/12/2025 | By News Bureau
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy